New York, May 09, 2016 -- Moody's Investors Service ("Moody's") today affirmed Albany Molecular Research Inc.'s (AMRI) ratings, including its B3 Corporate Family Rating (CFR), B3-PD Probability of Default Rating (PDR) and the B1 rating on the company's senior secured credit facilities. Moody's also affirmed AMRI's Speculative Grade Liquidity Rating of SGL-3. The rating outlook is stable.

Vollständigen Artikel bei Moodys lesen